Biocon to Add Pembrolizumab, Nivolumab & Trastuzumab SC Biosimilars to its Portfolio
On 6 January 2026, Biocon Biologics announced that it will unveil three new biosimilars at the 2026 J.P. Morgan Healthcare Conference to be held…
Pearce IP is Australia and New Zealand’s leading life sciences-focused intellectual property law firm.
Supporting life sciences clients from early-stage R&D through to commercial launch and beyond.
pearceIP.law | [email protected] | +61 2 9023 9988 | +64 4 886 1199
Popular articles from this firm
